Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
Identifieur interne : 000829 ( Main/Exploration ); précédent : 000828; suivant : 000830Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
Auteurs : Poupak Fallahi [Italie] ; Silvia Martina Ferrari [Italie] ; Giusy Elia [Italie] ; Francesca Ragusa [Italie] ; Sabrina Rosaria Paparo [Italie] ; Ilaria Ruffilli [Italie] ; Armando Patrizio [Italie] ; Gabriele Materazzi [Italie] ; Alessandro Antonelli [Italie]Source :
- Cancer Management and Research [ 1179-1322 ] ; 2019.
Abstract
Medullary thyroid cancers (MTCs) are neuroendocrine tumors, which secrete calcitonin and carcinoembryonic antigen, both of which can serve as tumor markers. Extensive and accurate surgical resection is the primary treatment for MTC, whereas the use of external beam radiotherapy is limited. Moreover, since MTC is derived from thyroid parafollicular cells or C cells, it is not responsive to either radioiodine or thyroid-stimulating hormone suppression, and therefore, they cannot be considered as treatment strategies. Traditional therapies for advanced or metastatic progressive medullary thyroid cancer (pMTC) are poorly effective. Among the new approaches tested in clinical trials, targeted chemotherapies with tyrosine kinase inhibitors (TKIs) are now available and they represent effective interventions for progressive disease, with additional investigational options emerging. This paper reviews the efficacy and safety of vandetanib in patients with a pMTC, as it has been shown to improve progression-free survival (30.5 vs 19.3 months in controls). Vandetanib is approved by the FDA and EMA for symptomatic or progressive MTC in patients with unresectable locally advanced or metastatic disease in adults, adolescents, and children older than 5 years. The most common adverse events in vandetanib-treated patients are diarrhea, rash, folliculitis, nausea, QTc prolongation, hypertension, and fatigue. More data are required to deepen our knowledge on molecular biology of tumor and host defense, with the aim to achieve better prognosis and higher quality of life for affected patients.
Url:
DOI: 10.2147/CMAR.S127848
PubMed: 31686907
PubMed Central: 6708888
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000444
- to stream Pmc, to step Curation: 000444
- to stream Pmc, to step Checkpoint: 000770
- to stream Ncbi, to step Merge: 000B71
- to stream Ncbi, to step Curation: 000B71
- to stream Ncbi, to step Checkpoint: 000B71
- to stream Main, to step Merge: 000829
- to stream Main, to step Curation: 000829
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes</title>
<author><name sortKey="Fallahi, Poupak" sort="Fallahi, Poupak" uniqKey="Fallahi P" first="Poupak" last="Fallahi">Poupak Fallahi</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Department of Translational Research and of New Technologies in Medicine and Surgery, University of Pisa</institution>
,<addr-line>Pisa</addr-line>
,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ferrari, Silvia Martina" sort="Ferrari, Silvia Martina" uniqKey="Ferrari S" first="Silvia Martina" last="Ferrari">Silvia Martina Ferrari</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Clinical and Experimental Medicine, University of Pisa</institution>
,<addr-line>Pisa</addr-line>
,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Elia, Giusy" sort="Elia, Giusy" uniqKey="Elia G" first="Giusy" last="Elia">Giusy Elia</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Clinical and Experimental Medicine, University of Pisa</institution>
,<addr-line>Pisa</addr-line>
,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ragusa, Francesca" sort="Ragusa, Francesca" uniqKey="Ragusa F" first="Francesca" last="Ragusa">Francesca Ragusa</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Clinical and Experimental Medicine, University of Pisa</institution>
,<addr-line>Pisa</addr-line>
,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Paparo, Sabrina Rosaria" sort="Paparo, Sabrina Rosaria" uniqKey="Paparo S" first="Sabrina Rosaria" last="Paparo">Sabrina Rosaria Paparo</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Clinical and Experimental Medicine, University of Pisa</institution>
,<addr-line>Pisa</addr-line>
,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ruffilli, Ilaria" sort="Ruffilli, Ilaria" uniqKey="Ruffilli I" first="Ilaria" last="Ruffilli">Ilaria Ruffilli</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Clinical and Experimental Medicine, University of Pisa</institution>
,<addr-line>Pisa</addr-line>
,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Patrizio, Armando" sort="Patrizio, Armando" uniqKey="Patrizio A" first="Armando" last="Patrizio">Armando Patrizio</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Clinical and Experimental Medicine, University of Pisa</institution>
,<addr-line>Pisa</addr-line>
,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Materazzi, Gabriele" sort="Materazzi, Gabriele" uniqKey="Materazzi G" first="Gabriele" last="Materazzi">Gabriele Materazzi</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0003"><institution>Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa</institution>
,<addr-line>Pisa</addr-line>
,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Antonelli, Alessandro" sort="Antonelli, Alessandro" uniqKey="Antonelli A" first="Alessandro" last="Antonelli">Alessandro Antonelli</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Clinical and Experimental Medicine, University of Pisa</institution>
,<addr-line>Pisa</addr-line>
,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">31686907</idno>
<idno type="pmc">6708888</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708888</idno>
<idno type="RBID">PMC:6708888</idno>
<idno type="doi">10.2147/CMAR.S127848</idno>
<date when="2019">2019</date>
<idno type="wicri:Area/Pmc/Corpus">000444</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000444</idno>
<idno type="wicri:Area/Pmc/Curation">000444</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000444</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000770</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000770</idno>
<idno type="wicri:Area/Ncbi/Merge">000B71</idno>
<idno type="wicri:Area/Ncbi/Curation">000B71</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000B71</idno>
<idno type="wicri:Area/Main/Merge">000829</idno>
<idno type="wicri:Area/Main/Curation">000829</idno>
<idno type="wicri:Area/Main/Exploration">000829</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes</title>
<author><name sortKey="Fallahi, Poupak" sort="Fallahi, Poupak" uniqKey="Fallahi P" first="Poupak" last="Fallahi">Poupak Fallahi</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0001"><institution>Department of Translational Research and of New Technologies in Medicine and Surgery, University of Pisa</institution>
,<addr-line>Pisa</addr-line>
,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ferrari, Silvia Martina" sort="Ferrari, Silvia Martina" uniqKey="Ferrari S" first="Silvia Martina" last="Ferrari">Silvia Martina Ferrari</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Clinical and Experimental Medicine, University of Pisa</institution>
,<addr-line>Pisa</addr-line>
,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Elia, Giusy" sort="Elia, Giusy" uniqKey="Elia G" first="Giusy" last="Elia">Giusy Elia</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Clinical and Experimental Medicine, University of Pisa</institution>
,<addr-line>Pisa</addr-line>
,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ragusa, Francesca" sort="Ragusa, Francesca" uniqKey="Ragusa F" first="Francesca" last="Ragusa">Francesca Ragusa</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Clinical and Experimental Medicine, University of Pisa</institution>
,<addr-line>Pisa</addr-line>
,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Paparo, Sabrina Rosaria" sort="Paparo, Sabrina Rosaria" uniqKey="Paparo S" first="Sabrina Rosaria" last="Paparo">Sabrina Rosaria Paparo</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Clinical and Experimental Medicine, University of Pisa</institution>
,<addr-line>Pisa</addr-line>
,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ruffilli, Ilaria" sort="Ruffilli, Ilaria" uniqKey="Ruffilli I" first="Ilaria" last="Ruffilli">Ilaria Ruffilli</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Clinical and Experimental Medicine, University of Pisa</institution>
,<addr-line>Pisa</addr-line>
,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Patrizio, Armando" sort="Patrizio, Armando" uniqKey="Patrizio A" first="Armando" last="Patrizio">Armando Patrizio</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Clinical and Experimental Medicine, University of Pisa</institution>
,<addr-line>Pisa</addr-line>
,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Materazzi, Gabriele" sort="Materazzi, Gabriele" uniqKey="Materazzi G" first="Gabriele" last="Materazzi">Gabriele Materazzi</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0003"><institution>Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa</institution>
,<addr-line>Pisa</addr-line>
,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Antonelli, Alessandro" sort="Antonelli, Alessandro" uniqKey="Antonelli A" first="Alessandro" last="Antonelli">Alessandro Antonelli</name>
<affiliation wicri:level="1"><nlm:aff id="AFF0002"><institution>Department of Clinical and Experimental Medicine, University of Pisa</institution>
,<addr-line>Pisa</addr-line>
,<country>Italy</country>
</nlm:aff>
<country xml:lang="fr">Italie</country>
<wicri:regionArea># see nlm:aff country strict</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Cancer Management and Research</title>
<idno type="eISSN">1179-1322</idno>
<imprint><date when="2019">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><title>Abstract</title>
<p>Medullary thyroid cancers (MTCs) are neuroendocrine tumors, which secrete calcitonin and carcinoembryonic antigen, both of which can serve as tumor markers. Extensive and accurate surgical resection is the primary treatment for MTC, whereas the use of external beam radiotherapy is limited. Moreover, since MTC is derived from thyroid parafollicular cells or C cells, it is not responsive to either radioiodine or thyroid-stimulating hormone suppression, and therefore, they cannot be considered as treatment strategies. Traditional therapies for advanced or metastatic progressive medullary thyroid cancer (pMTC) are poorly effective. Among the new approaches tested in clinical trials, targeted chemotherapies with tyrosine kinase inhibitors (TKIs) are now available and they represent effective interventions for progressive disease, with additional investigational options emerging. This paper reviews the efficacy and safety of vandetanib in patients with a pMTC, as it has been shown to improve progression-free survival (30.5 vs 19.3 months in controls). Vandetanib is approved by the FDA and EMA for symptomatic or progressive MTC in patients with unresectable locally advanced or metastatic disease in adults, adolescents, and children older than 5 years. The most common adverse events in vandetanib-treated patients are diarrhea, rash, folliculitis, nausea, QTc prolongation, hypertension, and fatigue. More data are required to deepen our knowledge on molecular biology of tumor and host defense, with the aim to achieve better prognosis and higher quality of life for affected patients.</p>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<affiliations><list><country><li>Italie</li>
</country>
</list>
<tree><country name="Italie"><noRegion><name sortKey="Fallahi, Poupak" sort="Fallahi, Poupak" uniqKey="Fallahi P" first="Poupak" last="Fallahi">Poupak Fallahi</name>
</noRegion>
<name sortKey="Antonelli, Alessandro" sort="Antonelli, Alessandro" uniqKey="Antonelli A" first="Alessandro" last="Antonelli">Alessandro Antonelli</name>
<name sortKey="Elia, Giusy" sort="Elia, Giusy" uniqKey="Elia G" first="Giusy" last="Elia">Giusy Elia</name>
<name sortKey="Ferrari, Silvia Martina" sort="Ferrari, Silvia Martina" uniqKey="Ferrari S" first="Silvia Martina" last="Ferrari">Silvia Martina Ferrari</name>
<name sortKey="Materazzi, Gabriele" sort="Materazzi, Gabriele" uniqKey="Materazzi G" first="Gabriele" last="Materazzi">Gabriele Materazzi</name>
<name sortKey="Paparo, Sabrina Rosaria" sort="Paparo, Sabrina Rosaria" uniqKey="Paparo S" first="Sabrina Rosaria" last="Paparo">Sabrina Rosaria Paparo</name>
<name sortKey="Patrizio, Armando" sort="Patrizio, Armando" uniqKey="Patrizio A" first="Armando" last="Patrizio">Armando Patrizio</name>
<name sortKey="Ragusa, Francesca" sort="Ragusa, Francesca" uniqKey="Ragusa F" first="Francesca" last="Ragusa">Francesca Ragusa</name>
<name sortKey="Ruffilli, Ilaria" sort="Ruffilli, Ilaria" uniqKey="Ruffilli I" first="Ilaria" last="Ruffilli">Ilaria Ruffilli</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000829 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000829 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Exploration |type= RBID |clé= PMC:6708888 |texte= Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:31686907" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a ChloroquineV1
This area was generated with Dilib version V0.6.33. |